Episode
Pluses and minuses of the weight-loss drug bonanza
- Podcast
- The Big View
- Published
- Nov 18, 2025
- Duration seconds
- 2061
- Processing state
not_requested- Canonical source
- https://pdst.fm/e/traffic.megaphone.fm/THRH2737040369.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/the-big-view-6037663/episodes/pluses-and-minuses-of-the-weight-loss-drug-bonanza/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-big-view-6037663/pluses-and-minuses-of-the-weight-loss-drug-bonanza.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Obesity treatments made by Novo Nordisk and Eli Lilly have spawned a healthcare revolution, with sales set to hit $150 bln by 2031. In this episode of The Big View, Peter Thal Larsen talks to Breakingviews Associate Editor Aimee Donnellan about their origins – and their impact. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices